This Case Report illustrates the ability to salvage high risk, multi-refractory t(11;14) patients with venetoclax. The depth of the response achieved indicates the importance of BCL-2 in mediating resistance in some patients with t(11;14) and suggests that at least in this patient population any risk of increased infection is likely justified by the potential benefit. Finally, our ability to administer this drug in the setting of ESRF argues for further studies evaluating the safety of venetoclax in patients with reduced renal function.
Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14) / Swan, Dawn; Delaney, Caoimhe; Natoni, Alessandro; O'Dwyer, Michael; Krawczyk, Janusz. - In: HAEMATOLOGICA. - ISSN 1592-8721. - 105:3(2020), pp. e141-e143. [10.3324/haematol.2019.228338]
Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14)
Natoni, Alessandro;
2020
Abstract
This Case Report illustrates the ability to salvage high risk, multi-refractory t(11;14) patients with venetoclax. The depth of the response achieved indicates the importance of BCL-2 in mediating resistance in some patients with t(11;14) and suggests that at least in this patient population any risk of increased infection is likely justified by the potential benefit. Finally, our ability to administer this drug in the setting of ESRF argues for further studies evaluating the safety of venetoclax in patients with reduced renal function.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
